(Total Views: 670)
Posted On: 06/14/2022 12:45:41 AM
Post# of 153941
Quote:
last year avisol capital partners praised the nash results of akero therapeutics
At the time they touted it the stock price was around $23 now it's $8.06.
What's very interesting is that initially Akero was pushing that it improved hepatic fat fraction and a reduction in fibrosis. A year later when they actually published in a peer review journal HFF was announced but not fibrosis. So, so many of the drugs tried for NASH reduced fat but all have failed.
https://www.fiercebiotech.com/biotech/analyst...best-class
https://www.nature.com/articles/s41591-021-01425-3#Bib1
(12)
(1)
